Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Med Case Rep ; 17(1): 156, 2023 Apr 08.
Article in English | MEDLINE | ID: covidwho-2296220

ABSTRACT

BACKGROUND: The use of hemoperfusion for cytokine removal and inflammatory mediators is increasingly intense, especially in coronavirus disease 2019 patients who are already known to the general public for having cytokine storms. However, we have known about these cytokine storms for a long time in the critical care world. One of the modalities to remove cytokines is to use filtration and adsorption techniques with continuous renal replacement therapy. The use of continuous renal replacement therapy is usually constrained by its very high cost compared with standard care, especially in Indonesia, where health costs are covered by national health insurance. In this case, we use hemodialysis and hemoperfusion, using a dialysis machine, which is more cost-effective and easy to use. CASE PRESENTATION: We used the Jafron HA330 cartridge, modified for the BBraun Dialog+ dialysis machine. This case report presents an 84-year-old Asian man with septic shock due to pneumonia, congestive heart failure, and acute chronic kidney disease accompanied by fluid overload. After undergoing hemodialysis and hemoperfusion separately, there was a gradual and significant clinical improvement. Clinical indicators, including the vasopressor inotropic score and infection markers, should all be considered when deciding whether to begin hemodialysis and hemoperfusion. CONCLUSION: In general, using hemoperfusion to treat septic shock patients can reduce the length of stay in the intensive care unit, and morbidity and mortality.


Subject(s)
COVID-19 , Hemoperfusion , Pneumonia , Shock, Septic , Male , Humans , Aged, 80 and over , Shock, Septic/complications , Shock, Septic/therapy , Hemoperfusion/methods , Cytokine Release Syndrome , Renal Dialysis/methods , COVID-19/therapy
2.
J Med Case Rep ; 17(1): 157, 2023 Apr 12.
Article in English | MEDLINE | ID: covidwho-2295911

ABSTRACT

BACKGROUND: Miliary tuberculosis is a life-threatening disease caused by the hematogenous spread of Mycobacterium tuberculosis. It is uncommon in pregnancy. Mortality rates for patients with miliary tuberculosis who require mechanical ventilation are high (60-70%). CASE PRESENTATION: We reported a rare and challenging case, a 35-year-old Asian woman with 34 weeks of pregnancy, and miliary tuberculosis with acute respiratory distress syndrome and septic shock. The patient presented with severe acute respiratory distress syndrome, necessitating mechanical ventilation, vasopressor, and pregnancy termination with caesarean section. The patient underwent blood purification with continuous veno-venous hemofiltration using an oXiris filter for 24 hours. After continuous veno-venous hemofiltration, the patient's condition was greatly improved, and the patient was successfully extubated and was able to breathe spontaneously without vasopressor on the third day. High levels of interleukin-6, interleukin-10, procalcitonin, C-reactive protein, interferon-γ, and tumor necrosis factor-α were found postoperatively. CONCLUSION: The bacterial infection of tuberculosis, acute respiratory distress syndrome, and the stress response from the caesarean section contributed to the high levels of cytokines, which correlated with the patient's severe inflammatory condition. The cytokine levels were greatly reduced after the blood purification procedure and this might be associated with the patient's clinical improvement. Extracorporeal blood purification could help to disrupt the vicious cycle of inflammation.


Subject(s)
Mycobacterium tuberculosis , Respiratory Distress Syndrome , Shock, Septic , Tuberculosis, Miliary , Humans , Pregnancy , Female , Adult , Tuberculosis, Miliary/complications , Cesarean Section/adverse effects , Respiratory Distress Syndrome/etiology , Shock, Septic/complications
3.
J Neurol Sci ; 443: 120485, 2022 Dec 15.
Article in English | MEDLINE | ID: covidwho-2105434

ABSTRACT

BACKGROUND: Scientific data regarding the prevalence of COVID-19 neurological manifestations and prognosis in Latin America countries is still lacking. Therefore, the study aims to understand neurological manifestations of SARS-CoV 2 infection and outcomes in the Brazilian population. METHODS: This study is part of the Brazilian COVID-19 Registry, a multicentric cohort, including data from 37 hospitals. For the present analysis, patients were grouped according to the presence of reported symptoms (i.e., headache; anosmia and ageusia; syncope and dizziness) vs. clinically-diagnosed neurological manifestations (clinically-defined neurological syndrome: neurological signs or diagnoses captured by clinical evaluation) and matched with patients without neurological manifestations by age, sex, number of comorbidities, hospital of admission, and whether or not patients had underlying neurological disease. RESULTS: From 6,635 hospitalized patients with COVID-19, 30.8% presented reported neurological manifestations, 10.3% were diagnosed with a neurological syndrome and 60.1% did not show any neurological manifestations. In patients with reported symptoms, the most common ones were headache (20.7%), ageusia (11.1%) and anosmia (8.0%). In patients with neurological syndromes, acute encephalopathy was the most common diagnosis (9.7%). In the matched analysis, patients with neurological syndromes presented more cases of septic shock (17.0 vs. 13.0%, p = 0.045), intensive care unit admission (45.3 vs. 38.9%, p = 0.023), and mortality (38.7 vs. 32.6%, p = 0.026; and 39.2 vs. 30.3%, p < 0.001) when compared to controls. CONCLUSION: COVID-19 in-hospital patients with clinically defined neurological syndromes presented a higher incidence of septic shock, ICU admission and death when compared to controls.


Subject(s)
Ageusia , COVID-19 , Shock, Septic , Humans , COVID-19/complications , COVID-19/epidemiology , Ageusia/epidemiology , Ageusia/etiology , SARS-CoV-2 , Anosmia , Shock, Septic/complications , Brazil/epidemiology , Headache/epidemiology , Headache/etiology , Hospitals
4.
Rev Med Chil ; 150(2): 266-270, 2022 Feb.
Article in Spanish | MEDLINE | ID: covidwho-1988174

ABSTRACT

Sepsis is one of the leading causes of death in critically ill patients with COVID-19 and blood purification therapies have a role to immunomodulate the excessive inflammatory response and improve clinical results. One of the devices designed for these therapies is the oXiris® filter, allowing to perform renal replacement therapy combined with selective adsorption of endotoxins and cytokines. We report a 55-year-old male with COVID who developed a septic shock secondary to a sepsis caused by Pseudomona aeruginosa, refractory to the usual management. A veno-venous continuous hemofiltration was started using the oXiris® filter for 48 hours. Subsequently, there was an improvement in clinical perfusion parameters and a reduction in inflammatory markers. The patient was discharged from the intensive care one month later.


Subject(s)
COVID-19 , Sepsis , Shock, Septic , COVID-19/complications , Cytokines , Endotoxins , Humans , Male , Middle Aged , Sepsis/complications , Shock, Septic/complications , Shock, Septic/therapy
5.
CNS Neurol Disord Drug Targets ; 20(5): 473-477, 2021.
Article in English | MEDLINE | ID: covidwho-1526730

ABSTRACT

INTRODUCTION: Catatonia is a psychomotor syndrome that presents with severe symptoms which can lead to dangerous and lethal conditions if not diagnosed and treated properly. SARS-- CoV-2 is a positive-sense single-stranded RNA virus that can occur in severe cases with acute pneumonia, ARDS, sepsis and septic shock. In these cases, ICU admission is necessary. CASE SUMMARY: A 59-year-old Caucasian man with septic shock and bilateral interstitial pneumonia from SARS-CoV-2 and schizotypal personality disorder presented with catatonic behaviour manifested by soporous state, response to intense painful stimuli with the opening of the eyes, execution of simple verbal commands, maintenance of the same position, catalepsy, immobility, rigidity and mutism. At the same time, there were symptoms of septic shock and catatonic symptoms, causing greater difficulty in the correct formulation of the diagnosis. During the course of his hospitalization, he was treated with asenapine 20 mg/day. The catatonia responded rapidly and significantly to the asenapine. DISCUSSION: To date, the pathophysiology of catatonia is unclear, and few guidelines are available for the treatment of catatonia. In the literature, studies have reported the efficacy of benzodiazepines such as lorazepam and diazepam, GABAA agonists such as zolpidem, NMDA receptor antagonists such as memantine, antidepressant SSRIs such as fluoxetine and paroxetine, and antipsychotics such as olanzapine, clozapine and aripiprazole. We demonstrate that the antipsychotic asenapine is also effective in treating catatonic symptoms in psychiatric disorders. CONCLUSION: Asenapine produced a rapid and significant reduction in catatonic symptoms in our patient with schizotypal personality disorder.


Subject(s)
Antipsychotic Agents/therapeutic use , COVID-19/complications , Catatonia/drug therapy , Catatonia/etiology , Depressive Disorder, Major/complications , Dibenzocycloheptenes/therapeutic use , Schizotypal Personality Disorder/complications , Shock, Septic/complications , Shock, Septic/etiology , Catatonia/psychology , Humans , Male , Middle Aged , Pain/etiology , Respiratory Distress Syndrome/complications
6.
Am J Health Syst Pharm ; 79(5): 329-337, 2022 02 18.
Article in English | MEDLINE | ID: covidwho-1450366

ABSTRACT

PURPOSE: To provide an overview of current literature on the pathophysiology of sepsis, with a focus on mediators of endothelial injury and organ dysfunction. SUMMARY: Sepsis is a dysregulated response to infection that triggers cascades of interconnected systems. Sepsis has been a significant cause of mortality worldwide, and the recent viral pandemic that may produce severe sepsis and septic shock has been a major contributor to sepsis-related mortality. Understanding of the pathophysiology of sepsis has changed dramatically over the last several decades. Significant insight into the components of the inflammatory response that contribute to endothelial injury and trigger coagulation pathways has been achieved. Similarly, characterization of anti-inflammatory pathways that may lead to secondary infections and poor outcome has illustrated opportunities for improved therapies. Description of an increasing number of important mediators and pathways has occurred and may point the way to novel therapies to address immune dysregulation. Pharmacists will need a fundamental understanding of the overlapping pathways of the immune response to fully prepare for use of novel treatment options. While pharmacists typically understand coagulation cascade how to utilize anticoagulants, the issues in sepsis related coagulopathy and role of mediators such as cytokines and complement and role of activated platelets and neutrophils require a different perspective. CONCLUSION: Pharmacists can benefit from understanding both the cellular and organ system issues in sepsis to facilitate assessment of potential therapies for risk and benefit.


Subject(s)
Blood Coagulation Disorders , Sepsis , Shock, Septic , Anticoagulants , Blood Coagulation/physiology , Blood Coagulation Disorders/etiology , Blood Coagulation Disorders/therapy , Humans , Shock, Septic/complications
8.
A A Pract ; 14(9): e01287, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-992616

ABSTRACT

Methemoglobinemia is a rare disorder of the blood in which there is an increase in methemoglobin, which occurs when hemoglobin is present in the oxidized form. Methemoglobin impairs hemoglobin's ability to transport oxygen, produces functional anemia, and leads to tissue hypoxia. We report the successful management of a case of refractory hypoxia due to acutely acquired methemoglobinemia in a patient undergoing treatment for coronavirus disease 2019 (COVID-19) pneumonia. The cause of methemoglobinemia in this patient remains unknown. Hypoxia and methemoglobinemia did not respond to methylene blue and required administration of packed red blood cell transfusions.


Subject(s)
Coronavirus Infections/complications , Hypoxia/etiology , Methemoglobinemia/complications , Pneumonia, Viral/complications , Respiratory Insufficiency/etiology , Acute Kidney Injury/complications , Acute Kidney Injury/therapy , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Betacoronavirus , COVID-19 , Coronavirus Infections/drug therapy , Corynebacterium , Corynebacterium Infections/complications , Corynebacterium Infections/therapy , Cytokine Release Syndrome/complications , Enzyme Inhibitors/therapeutic use , Erythrocyte Transfusion , Hematinics/therapeutic use , Humans , Hydroxocobalamin/therapeutic use , Hydroxychloroquine/therapeutic use , Hypoxia/therapy , Male , Methemoglobinemia/therapy , Methylene Blue/therapeutic use , Pandemics , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/therapy , Pneumonia, Viral/drug therapy , Renal Replacement Therapy , Respiratory Insufficiency/therapy , SARS-CoV-2 , Shock, Septic/complications
9.
Shock ; 55(4): 479-487, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-744652

ABSTRACT

BACKGROUND: Acute kidney injury (AKI) is a common complication of COVID-19 critical illness but the pathophysiology is uncertain. Some evidence has indicated that a vascular aetiology may be implicated. We used contrast-enhanced ultrasound (CEUS) and echocardiography to study renal perfusion and global blood flow and compared our findings with measurements taken in a group of septic shock patients and healthy volunteers. METHODS: Prospective case-control study. Renal perfusion variables were assessed with CEUS; macrovascular blood flow was assessed using Doppler analysis of large renal vessels; echocardiography was used to assess right and left heart function and cardiac output. RESULTS: CEUS-derived parameters were reduced in COVID-19 associated AKI compared with healthy controls (perfusion index 3,415 vs. 548 a.u., P = 0·001; renal blood volume 7,794 vs. 3,338 a.u., P = 0·04). Renal arterial flow quantified using time averaged peak velocity was also reduced compared with healthy controls (36·6 cm/s vs. 20·9 cm/s, P = 0.004) despite cardiac index being similar between groups (2.8 L/min/m2 vs. 3.7 L/min/m2, P = 0.07). There were no differences in CEUS-derived or cardiac parameters between COVID-19 and septic shock patients but patients with septic shock had more heterogeneous perfusion variables. CONCLUSION: Both large and small vessel blood flow is reduced in patients with COVID-19 associated AKI compared with healthy controls, which does not appear to be a consequence of right or left heart dysfunction. A reno-vascular pathogenesis of COVID-19 AKI seems likely.


Subject(s)
Acute Kidney Injury/physiopathology , COVID-19/complications , COVID-19/physiopathology , Critical Illness , Heart Function Tests , Renal Circulation/physiology , Ultrasonography , Acute Kidney Injury/diagnostic imaging , Aged , COVID-19/diagnostic imaging , Case-Control Studies , Contrast Media , Female , Humans , Male , Middle Aged , Prospective Studies , Regional Blood Flow/physiology , Shock, Septic/complications , Shock, Septic/physiopathology
10.
Cell Mol Immunol ; 17(9): 992-994, 2020 09.
Article in English | MEDLINE | ID: covidwho-630398
12.
Chest ; 158(2): e55-e58, 2020 08.
Article in English | MEDLINE | ID: covidwho-211230

ABSTRACT

We report the case of an 88-year-old man with coronavirus disease 2019 (COVID-19) who presented with ARDS and septic shock. The patient had exquisite BP sensitivity to low-dose angiotensin II (Ang-2), allowing for rapid liberation from high-dose vasopressors. We hypothesize that sensitivity to Ang-2 might be related to biological effect of severe acute respiratory syndrome coronavirus 2 infection. The case is suggestive of a potential role for synthetic Ang-2 for patients with COVID-19 and septic shock. Further studies are needed to confirm our observed clinical efficacy.


Subject(s)
Angiotensin II/metabolism , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Respiratory Distress Syndrome/drug therapy , Shock, Septic/drug therapy , Aged, 80 and over , Angiotensin II/drug effects , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/metabolism , Humans , Male , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/metabolism , Respiratory Distress Syndrome/etiology , SARS-CoV-2 , Shock, Septic/complications , Shock, Septic/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL